SCHEMBL203385

SCHEMBL203385

OCc1cc(Br)ccc1-c1ccc(Br)cc1CO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
ALOX15 P16050 1/20 0.42
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
S100A4 P26447 1/20 0.41
BCL2 P10415 1/20 0.39
MCL1 Q07820 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
NPC1 O15118 3/20 0.38
CHEK1 O14757 1/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12798314 0.89 PTGDR2 (0.43) PTGDR2SLC6A2SLC6A4S100A4BCL2
SCHEMBL1988581 0.85 PTGDR2 (0.46) PTGDR2SLC6A2SLC6A4NPC1ALDH1A1
SCHEMBL31468792 0.83 PTGDR2 (0.37) PTGDR2SLC6A2SLC6A4CA1CA2
SCHEMBL12849035 0.83 KDM4E (0.45) PTGDR2ALOX15ALDH1A1MAPTHSD17B10
SCHEMBL4587479 0.83 MAPK1 (0.41) PTGDR2SLC6A2SLC6A4CA1CA2
SCHEMBL29417721 0.82 PTGDR2 (0.48) PTGDR2ALOX15SLC6A2SLC6A4NPC1
SCHEMBL795719 0.82 PTGDR2 (0.48) PTGDR2ALOX15SLC6A2SLC6A4NPC1
SCHEMBL17868453 0.80 PTGDR2 (0.43) PTGDR2ALOX15SLC6A2SLC6A4S100A4
SCHEMBL1047305 0.80 PTGDR2 (0.47) PTGDR2ALOX15SLC6A2SLC6A4S100A4
SCHEMBL29870381 0.78 ALOX15 (0.52) PTGDR2ALOX15SLC6A2SLC6A4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 EP disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 EP disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 EP disclosed
EP-3002281-B1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2017-09-13 EP disclosed
EP-3002281-B1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2017-09-13 EP disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 US disclosed
US-9511056-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2016-12-06 US disclosed
US-20090202483-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 US disclosed
US-7462683-B2 Dihalide, polymer compound and method for producing the same TOKYO INSTITUTE OF TECHNOLOGY (JP) 2008-12-09 US disclosed
US-20070185306-A1 Dihalide, polymer compound and method for producing the same TOKYO INSTITUTE OF TECHNOLOGY (JP) 2007-08-09 US disclosed
US-20070185306-A1 Dihalide, polymer compound and method for producing the same TOKYO INSTITUTE OF TECHNOLOGY (JP) 2007-08-09 US disclosed
US-20070034832-A1 (Partially) conjugated polymer, process for its preparation and use in electroluminescent devices CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2007-02-15 US disclosed
US-20070034832-A1 (Partially) conjugated polymer, process for its preparation and use in electroluminescent devices CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2007-02-15 US disclosed
EP-1717258-A1 DIHALIDE, POLYMER COMPOUND AND METHOD FOR PRODUCING SAME Tokyo Institute of Technology (JP) 2006-11-02 EP disclosed
EP-1325054-B1 TWISTED POLYMERS, USES THEREOF AND PROCESSES FOR THE PREPARATION OF STATISTICAL COPOLYMERS CAMBRIDGE DISPLAY TECH LTD (GB) 2006-07-19 EP disclosed
US-6949291-B2 Twisted polymers, uses thereof and processes for the preparation of statistical copolymers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2005-09-27 US disclosed
US-20040097699-A1 Twisted polymers, uses thereof and processes for the preparation of statistical copolymers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185306-A1 Dihalide, polymer compound and method for producing the same HSPA4L, HDHD5, MRPL21 PTGDR2 3232/4885ALOX15 3235/4885SLC6A2 3577/4885
US-20170029408-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 PTGDR2 4829/4885ALOX15 2962/4885SLC6A2 4103/4885
US-20090202483-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS PTGDR2 3993/4885ALOX15 2436/4885SLC6A2 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.